Earnings

Quest Diagnostics Raises FY2026 Adj EPS Guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 Est; Raises FY2026 Sales Guidance from $11.950B-$12.050B to $12.065B-$12.105B vs $12.001B Est

Oct 22, 2026 · 06:49 AM ET· updated 1h ago

Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 analyst estimate. Raises FY2026 sales outlook from $11.950 billion-$12.050 billion to $12.065 billion-$12.105

Why It Matters

Quest Diagnostics says it will make more money and sell more stuff next year. When a company raises its own forecast, watch if it keeps delivering on those bigger promises.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

DGX230.58

-8.35 (-3.49%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.